osteoporosis drugs market

1
Osteoporosis Drugs Market 

• Osteoporosis Drugs Market to Reach 10.47 Billion
  by 2026 AMR

2
Prime Determinants of Growth  ?

• According to the report published by Allied
  Market Research, the global Osteoporosis Drugs
  Market held nearly 7.65 billion in 2018, and is
  projected to reach 10.47 billion by 2026,
  growing at a CAGR of 3.9 from 2019 to 2026. The
  report provides an extensive analysis of changing
  market trends, market size, trends,
  estimations, top investment pockets, key
  segments, and competitive scenarios.
• Increase in prevalence of osteoporosis, increase
  in the aging population, and adoption of
  sedentary lifestyle across the world drive the
  growth of the global osteoporosis drugs market.
  However, side effects related to osteoporosis
  drugs and time-consuming approval processes for
  drugs hinder the market growth. On the other
  hand, high potential for growth in developing
  countries would offer new opportunities in the
  coming years.

3
(No Transcript)
4
Regional Analysis 
North America held the largest market share in
terms of revenue, contributing to nearly half of
the total share in 2018, and is estimated to
maintain its dominant share during the forecast
period. However, LAMEA is estimated to witness
the highest CAGR of 5.5 from 2019 to 2026.
Asia-Pacific is expected to maintain a CAGR of
4.4 during the forecast period.
5
Leading Market Players?

• F. Hoffmann-La Roche AG
• Takeda Pharmaceutical Company Limited
• Novartis International AG (Sandoz)
• Merck Co. Inc.
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

6
Contact

• David Correa
• 5933 NE Win Sivers Drive205, Portland,
  OR 97220United StatesToll Free
  1-800-792-5285 UK 44-845-528-1300Hong Kong
  852-301-84916India (Pune) 91-20-66346060Fax
  1-855-550-5975help_at_alliedmarketresearch.comWeb
   https//www.alliedmarketresearch.com  Follow Us
  on LinkedIn Twitter